StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) income statement

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$2.98−0.11 (-3.56%)

Close on Nov 18, 2026Market cap $295.46MP/E –Yield –

X4 Pharmaceuticals, Inc income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
68.8%
Operating margin
-812.0%
Net margin
-813.3%
Return on equity, FY2025
-76.0%

Financial strength

Current ratio
13.22
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1240.0%

Valuation

P/E ratio
–
Price to sales
29.84
Price to book
2.13
Dividend yield
–

See a number that looks wrong?